Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease

Highlights

- Recombinant NDV passively incorporates SARS-CoV-2 spike into the virion
- Vaccination with NDV expressing SARS-CoV-2 spike protects hamsters from disease
- No infectious SARS-CoV-2 was detectable in the lungs of vaccinated hamsters
- NDV-vectored vaccines represent a viable option for protection against COVID-19
Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease

Bryce M. Warner,1,5 Lisa A. Santry,2,5 Alexander Leacy,2,5 Mable Chan,1,5 Phuc H. Pham,2,5 Robert Vendramelli,1,5 Yanlong Pei,2,5 Nikesh Tailor,1,4 Emelissa Valcourt,1 Anders Leung,1 Shihua He,1 Bryan D. Griffin,1 Jonathan Audet,1 Marnie Willman,3 Kevin Tierney,1 Alixandra Albietz,1 Kathy L. Frost,1 Jacob G.E. Yates,2 Robert C. Mould,2 Lily Chan,2 Yeganeh Mehrani,2 Jason P. Knapp,2 Jessica A. Minott,2 Logan Banadyga,1 David Safronetz,1,3 Heidi Wood,1 Stephanie Booth,1 Pierre P. Major,4 Byram W. Bridle,2,6 Leonardo Susta,2,6 Darwyn Kobasa,1,3,6 and Sarah K. Wootton2,6,7,*

SUMMARY
The pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19). Worldwide efforts are being made to develop vaccines to mitigate this pandemic. We engineered two recombinant Newcastle disease virus (NDV) vectors expressing either the full-length SARS-CoV-2 spike protein (NDV-FLS) or a version with a 19 amino acid deletion at the carboxy terminus (NDV-Δ19S). Hamsters receiving two doses (prime-boost) of NDV-FLS developed a robust SARS-CoV-2-neutralizing antibody response, with elimination of infectious virus in the lungs and minimal lung pathology at five days post-challenge. Single-dose vaccination with NDV-FLS significantly reduced SARS-CoV-2 replication in the lungs but only mildly decreased lung inflammation. NDV-Δ19S-treated hamsters had a moderate decrease in SARS-CoV-2 titers in lungs and presented with severe microscopic lesions, suggesting that truncation of the spike protein was a less effective strategy. In summary, NDV-vectored vaccines represent a viable option for protection against COVID-19.

INTRODUCTION
The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in late 2019 in the city of Wuhan, mainland China, as the causative agent of a severe respiratory disease named coronavirus disease 2019 (COVID-19) (Andersen et al., 2020; Zhou et al., 2020). The virus has been classified in the Coronaviridae family, β-coronavirus genus, and Sarbecovirus subgenus (i.e., β-coronavirus subgroup B) (Lu et al., 2020). Phylogenetic analysis has shown that this virus shares ~50% genetic similarity with Middle East respiratory syndrome-CoV, ~80% similarity with SARS-CoV, and >90% similarity with bat β-coronaviruses, suggesting spillover of the virus from bats to humans, possibly through an intermediate adaptive host (El Zowalaty and Jarhult, 2020; Frutos et al., 2020; Lu et al., 2020).

On March 11, 2020, a COVID-19 global pandemic was declared by the World Health Organization (WHO), and by April 2021, the disease had spread worldwide, with over 146 million confirmed cases and more than three million deaths ([WHO], last accessed 2020.09.07). Crude fatality rates have been reported to be around 4% (Karadag, 2020; Verity et al., 2020), although recent estimates that adjusted for demography and case under-ascertainment range between 0.15 and 1.5% (Ioannidis, 2021; Mallapaty, 2020; Russell et al., 2020). The elderly, people with hypertension, immunosuppression, diabetes, and obesity, among other pre-existing conditions, are at a heightened risk of developing severe disease (Williamson et al., 2020).

SARS-CoV-2 is transmitted through respiratory droplets and contact routes (Chan et al., 2020b; Li et al., 2020a; Liu et al., 2020; Ong et al., 2020). In people with severe disease, morbidity and mortality are
mediated by severe respiratory distress syndrome and vascular disease. The former is caused by diffuse alveolar damage associated with virus replication in type I and II alveolar pneumocytes (Bradley et al., 2020; Calabrese et al., 2020; Martines et al., 2020). Lesions not associated with the respiratory system include endothelial damage, thrombosis, and disseminated intravascular coagulation; however, compelling evidence of virus replication in the endothelium is lacking both in human natural cases or animal models (Besutti et al., 2020; Bradley et al., 2020; Martines et al., 2020; Sia et al., 2020; Varga et al., 2020). Molecular effectors of tissue damage include unchecked production of pro-inflammatory cytokines (i.e., cytokine storm), decreased angiotensin-converting enzyme-2 (ACE2) activity, and activation of a thrombo-inflammatory cascade leading to a hypercoagulable state (Domingo et al., 2020).

Not surprising, multiple research groups have developed vaccine platforms against SARS-CoV-2, including recombinant viral vectors, nucleic acids (DNA, mRNA, and self-replicating RNA), protein subunits, virus-like particles, and live-attenuated or inactivated SARS-CoV-2 virions (Jeyanathan et al., 2020). The vast majority of these vaccines target the SARS-CoV-2 spike (S) protein, the main target antigen for neutralizing antibodies against the virus (Ziegler et al., 2020). By the spring of 2021, in the United States and Canada, two mRNA vaccines, as well as one or two adenovirus-vectorized vaccines, respectively, have been approved for emergency use (https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines). However, it is unclear how these vaccines will be able to curtail the spread of and morbidity caused by novel SARS-CoV-2 variants, such as the B.1.351 (South African variant) and B1.617.2 (Indian/Delta variant), which have been detected since late 2020 (Kriola, 2021) (Kupferschmidt, 2021). Evolution of variants of concerns has highlighted the importance of sterilizing immunity to prevent circulation of SARS-CoV-2 in a partially vaccinated population, an occurrence that can promote development of escape virus mutants due to immunological selective pressure (Peiris and Leung, 2020).

Newcastle disease virus (NDV) has been extensively investigated as a candidate recombinant live vaccine platform for human and veterinary infectious diseases (Kim and Samal, 2016) and shows great potential as a vaccine against SARS-CoV-2 (Shirvani and Samal, 2020). NDV is the type-species of the avian orthoavulavirus-1 (AOaV-1) group, in the Paramyxoviridae family (Rima et al., 2019); this virus is enveloped and has a non-segmented, negative-strand RNA genome that allows insertion of foreign genes (up to ~5kb), which are stably expressed at high levels (Zhao et al., 2015). The use of NDV as a candidate vaccine vector in humans offers several advantages. As an avian virus, NDV is antigenically distinct from common human vaccines and pathogens, avoiding the problem of pre-existing immunity that would limit its efficacy in people (Capua and Alexander, 2004). More importantly, as an oncolytic agent NDV has shown an excellent safety profile, whereby direct intravenous, aerosol, or intratumoral administration of large doses of the virus are well tolerated in people (Csatty et al., 1993; Pecora et al., 2002; Wheelock and Dingle, 1964). As a vaccine vector in pre-clinical models, NDV has been shown to be safe and protective in non-human primate models of infection with pathogenic avian influenza virus, Ebola virus, and SARS-CoV (Bukreyev et al., 2005; DiNapoli et al., 2007, 2010). Lastly, NDV is an acute cytoplasmic virus with an encapsidated genome, mitigating concerns about recombination or tissue persistence (Afonso, 2008; Shirvani and Samal, 2020).

In this study, we show the efficacy of an intra-nasally delivered, non-virulent NDV vaccine expressing the SARS-CoV-2 S protein in a Syrian hamster model of COVID-19, by analysis of nasal and lung tissues at the peak of SARS-CoV-2 replication. The use of a non-virulent NDV strain (i.e., lentogenic pathotype which does not cause disease in poultry) circumvents regulatory restriction associated with livestock safety (Cattoli et al., 2011), and the intranasal delivery was aimed at developing mucosal, as well as systemic immunity (Calzas and Chevalier, 2019).

RESULTS
Development of recombinant NDV vectors expressing SARS-CoV-2 spike proteins

In this study, we utilized a fully synthetic molecular clone of lentogenic NDV (LaSota strain, GenBank: AF077761.1) flanked at the 5′ end by a T7 promoter followed by three non-templated G’s and at the 3′ by a self-cleaving hepatitis delta virus ribozyme and a T7 terminator sequence (Figure 1A). The ribozyme, by self-cleaving immediately at the end of the viral antigenomic transcript, ensures adherence to the “rule of six” of genomic length (Kolakofsky et al., 1998). The synthetic genome was designed to contain an additional transcriptional cassette between the phosphoprotein (P) and the matrix (M) genes, which was flanked by unique XbaI and MluI restriction sites (to facilitate transgene insertion), and gene start and gene end signals to promote transcription by the viral polymerase (Park et al., 2006). An additional L289A mutation
in the fusion (F) gene was included to enhance fusogenicity (Sergel et al., 2000). Three recombinant NDV vectors were designed by cloning in a transcriptional cassette expressing either (1) the complete coding sequence of human codon-optimized SARS CoV-2 S protein (NDV-FLS), (2) the partial coding sequence of human codon-optimized spike protein possessing a 19 amino acid deletion from the C-terminus (NDV-Δ19S), and (3) the coding sequence of the enhanced green fluorescent protein (GFP), an immunologically irrelevant protein, to be used as a control (NDV-GFP) (Figure 1A). The truncated version of the spike protein was included as this mutation has been shown to promote more efficient incorporation of spike into the fusion (F) gene was included to enhance fusogenicity (Sergel et al., 2000). Three recombinant NDV vectors were designed by cloning in a transcriptional cassette expressing either (1) the complete coding sequence of human codon-optimized SARS CoV-2 S protein (NDV-FLS), (2) the partial coding sequence of human codon-optimized spike protein possessing a 19 amino acid deletion from the C-terminus (NDV-Δ19S), and (3) the coding sequence of the enhanced green fluorescent protein (GFP), an immunologically irrelevant protein, to be used as a control (NDV-GFP) (Figure 1A). The truncated version of the spike protein was included as this mutation has been shown to promote more efficient incorporation of spike into
lentiviral particles and vesicular stomatitis virus (Fukushi et al., 2005; Johnson et al., 2020) particles. Successful rescue of recombinant viruses was verified by immunofluorescence staining for the ribonucleoprotein (RNP) complex in NDV-FLS-, NDV-Δ19S-, and NDV-GFP-infected DF-1 chicken fibroblasts (Figure 1B), and by reverse transcription polymerase chain reaction (RT-PCR) to confirm insertion of the spike gene in the viral genome (Figure 1C).

The full-length, but not the Δ19 truncated version, of SARS-CoV-2 spike protein is efficiently incorporated into NDV virions

Western blot analysis of whole cell lysates from DF-1 cells infected at the same multiplicity of infection (MOI = 1) with NDV-FLS or NDV-Δ19S showed robust expression of the full-length S protein at approximately 180 KDa, which was more intensely expressed in NDV-Δ19S- compared with NDV-FLS-infected cells (Figure 2A). Similarly, the cleaved S2 subunit migrated at approximately 100 KDa and was more intensely expressed in NDV-Δ19S- compared with NDV-FLS-infected cells (Figure 2A). To investigate whether the S protein expressed by the NDV vector would be incorporated into the virion and to compare expression with the challenge virus, SARS-CoV-2 and vaccine viruses (NDV-FLS and NDV-Δ19S) were subjected to Western blot analysis. As shown in Figure 2B, SARS-CoV-2 virions incorporated approximately equal amounts of uncleaved and cleaved S protein, as shown by bands right below 200 KDa and one at 100 KDa, respectively, while the virion of the NDV-FLS virus incorporated almost exclusively cleaved S protein. Despite the fact that NDV-Δ19S- infected cells expressed more S protein, this was poorly incorporated into the NDV-Δ19S virions. Nevertheless, S protein expressed from NDV migrated with a similar molecular weight and pattern to that of SARS-CoV-2 S protein.

When incorporated in the NDV virion, the S protein appeared in the cleaved form at around 100 KDa. This suggests efficient cleavage due to the multibasic cleavage site (Ou et al., 2020), a feature that was likely enhanced by the proteolytic activity of the allantoic fluid (Kandeil et al., 2014), as NDV-FLS and NDV-Δ19S were grown in eggs.

Taken together, these data demonstrate that NDV can be engineered to express the SARS-CoV-2 spike protein and that the full-length spike protein is incorporated into the NDV virion more efficiently than the Δ19 truncated version.

NDV vectors expressing SARS-CoV-2 spike proteins do not show an altered infectivity

To test whether the spike protein incorporation into the NDV virion would increase NDV infectivity, we conducted virus neutralization assays in HEK 293T cells over-expressing human ACE2, the receptor for SARS-CoV-2 (Ziegler et al., 2020). Mouse serum, which successfully neutralized lentiviral particles pseudotyped with the S protein in a separate experiment, did not neutralize NDV-FLS or NDV-Δ19S as shown by immunofluorescent staining for NDV RNP at three days post-infection (Figure S2). Instead, immune serum from chickens vaccinated with NDV completely neutralized the viruses (Figure S2). This indicates that incorporation of S protein on the surface of the NDV virion does not alter infectivity or tropism of the vaccine backbone.

To investigate whether expression of the S protein would impact the fusogenic properties of the recombinant NDV vaccines, DF-1 cells were infected with NDV-FLS, NDV-Δ19S, or NDV-GFP, and the number of nuclei was averaged over the total number of cells, with syncytia counted as one cell. As shown in Figure 2C, all three viruses formed syncytia in the presence of trypsin; however, NDV-FLS showed a significantly decreased fusogenic activity compared with either NDV-Δ19S or NDV-GFP (Figure 2D).

Finally, to confirm that the modifications to the NDV vector did not alter its virulence in poultry, we determined the mean death time (MDT) of NDV-FLS, NDV-Δ19S, and NDV-GFP in embryonated chicken eggs. All viruses had an MDT >110 h and thus retained their lentogenic phenotype. Overall, these data demonstrate that NDV engineered to express the SARS-CoV-2 spike protein do not display an altered safety profile in vitro and in ovo.

NDV vectors expressing SARS-CoV-2 spike proteins are immunogenic in hamsters

We wanted to determine whether vaccination with either the NDV expressing full-length or the truncated spike protein would protect against disease in a hamster model of SARS-CoV-2 infection. Groups of ten Syrian hamsters received intranasal instillations of 10⁷ plaque-forming units (PFUs) of either NDV-FLS,
NDV-Δ19S, or NDV-GFP (control), as part of a single dose or a two-dose schedule (Figure 3A). At 29 days after the first vaccine dose, low anti-SARS-CoV-2 immunoglobulin (IgG) titers were detected by enzyme-linked immunosorbent assay (ELISA) in the serum of hamsters receiving the NDV-FLS vaccine, while the
IgG levels in the NDV-D19S-treated animals were indistinguishable from those treated with NDV-GFP (Figure 3B). Neutralizing antibodies, detected by plaque reduction neutralization test (PRNT90) titers, were only detectable in a single animal in the NDV-FLS group prior to the second vaccine dose (Figure 3C). Following a second homologous vaccine dose, a substantial induction of anti-SARS-CoV-2 humoral immune responses occurred, with a significant increase in serum IgG titers seen in both vaccine groups (Figure 3B), and a significant increase in PRNT90 titers in hamsters receiving NDV-FLS (Figure 3C). Only two (of ten) NDV-D19S-vaccinated hamsters had PRNT90 titers detectable 20 days following the second dose; however, this response waned by the challenge day (Figure 3C). The serum concentration of anti-SARS-CoV-2 IgG and neutralizing titers were significantly higher in the NDV-FLS-treated group, compared to the NDV-D19S- and NDV-GFP-treated groups, suggesting that incorporation of the spike protein into the NDV virion may be required for stronger induction of antibody responses. Our data show that a homologous prime-boost vaccination with NDV expressing SARS-CoV-2 spike protein is highly immunogenic in hamsters.

**Vaccination of hamsters with NDV vectors expressing SARS-CoV-2 S protects against SARS-CoV-2-induced clinical signs and pathology**

To determine whether immune responses in animals receiving a single dose or a homologous prime-boost would result in protection from disease, each of the groups of hamsters described above, which were vaccinated with 10⁷ PFU NDV-FLS, NDV-D19S, or NDV-GFP, were challenged with 10⁵ fifty-percent tissue culture infective dose (TCID₅₀) of SARS-CoV-2 on day 56 post-vaccination. An additional experiment was carried out by infecting hamsters at 28 days after receiving the prime only, using the same methodology. Animals were weighed and monitored daily for signs of disease throughout the course of infection. Of ten animals in each group, four were kept for 28 days to examine any differences in weight loss and long-term outcome of infection, while six were euthanized on day five post-infection to examine pathology and viral loads in the tissues during acute infection.

In the single-dose group, NDV-FLS-vaccinated hamsters had significantly less weight loss on day 4 post-infection compared with the NDV-GFP and NDV-D19S-vaccinated hamsters. The NDV-D19S-vaccinated hamsters showed similar weight loss to controls, including several animals that lost greater than 10% of their initial weight within five days (Figure 4A). In the prime-boost group, the mean weight loss of the
NDV-FLS-treated hamsters was significantly less than NDV-GFP-treated hamsters on days 3, 4, and 5 post-infection (Figure 4B). Surprisingly, in the NDV-GFP-vaccinated animals, we did not see the weight loss that is typically seen in our hamster model and that has been reported by other groups (Imai et al., 2020). Of the four animals that were not euthanized, none reached greater than 5% weight loss following infection throughout the 28 days, while five of six of the euthanized animals had as high as 8% weight loss and were trending downward. These animals were likely euthanized before reaching peak weight loss, thereby artificially skewing the mean weight loss of that group.

The magnitude of microscopic lesions in the lungs was assessed semi-quantitatively, in order to evaluate the efficacy of the vaccine candidates to decrease the severity of lesions associated with SARS-CoV-2 infection. For both the prime and prime-boost experiments, nominal reporting of lesion categories for each hamster is summarized in Tables S1 and S2, while the extent of affected lung tissue area is reported in Table S3.

Lesions in the control hamsters were similar between the prime only and prime-boost groups (Table S2; see below for a detailed description of histopathology). In the prime only cohort, when the compound score of nominal categories was considered, NDV-FLS-treated hamsters had significantly lower scores compared to the NDV-Δ19S-, but not the NDV-GFP-treated group (Figure 4C). Similarly, NDV-FLS-treated hamsters had...
| NDV-GFP | NDV-Δ19S | NDV-FLS |
|--------|----------|---------|
| ![Image A] | ![Image B] | ![Image C] |
| ![Image D] | ![Image E] | ![Image F] |
| ![Image G] | ![Image H] | ![Image I] |
| ![Image J] | ![Image K] | ![Image L] |
| ![Image M] | ![Image N] | ![Image O] |
significantly less extensive areas of lung pathology compared with the NDV-Δ19S - but not the NDV-GFP-treated group (Figure 4D). In the prime-boost cohort, the mean compound nominal score was significantly lower in NDV-FLS-treated hamsters compared to those in the NDV-GFP group; differences were not significant between the scores of the NDV-Δ19S- and NDV-GFP- or NDV-FLS-treated groups (Figure 4E).

Lastly, NDV-GFP- and NDV-Δ19S-treated hamsters had the highest extent of lesions, with five of six and three of six animals showing >50% of lung tissue affected, respectively; while in the NDV-FLS-treated group no hamsters had lesions in >50% of lung sections (Table S3). The average affected area scores were significantly different between NDV-FLS-treated hamsters and those in the NDV-GFP-treated group (Figure 4F).

In the prime-boost experiment, all hamsters treated with NDV-GFP presented with severe exudative lesions characterized by accumulation of sloughed cells, macrophages and neutrophils within the alveolar spaces, variably admixed with multifocal areas of hemorrhage and edema (Figures 5A, 5D, and 5G). In every hamster of this group, most bronchioles were filled with cellular debris and neutrophils. The connective tissues surrounding vessels and bronchioles was markedly expanded by edema and populated by inflammatory cells, such as macrophages, lymphocytes, fewer plasma cells, and scattered neutrophils. In all six hamsters, medium-size vessels showed segmental hyperplasia of the endothelial cells and sub-intimal accumulation of inflammatory cells, although no thrombosis was observed (Figure 5J). As animals were euthanized at day five pi, subacute changes were also observed, which included type II cell hyperplasia (Figure 5M), and presence of hemosiderin-laden macrophages mainly around the terminal bronchioles. In hamsters vaccinated with NDV-Δ19S (Figures 5B, 5E, 5H, 5K, and 5N), lesions were similar to the NDV-GFP-treated group, although the exudative changes were less prominent, noticeably with decreased amounts of desquamated cells in the alveolar spaces and bronchioles. In this group, most hamsters presented with numerous hemosiderin-laden macrophages (suggesting resolving hemorrhage) either in the alveoli or around bronchioles, type II cell hyperplasia (six of six hamsters), and marked hyperplasia of the bronchiolar epithelium in three of six hamsters (Figure 5N). In hamsters vaccinated with NDV-FLS, only two of six hamsters showed mild exudation of neutrophils in the alveoli, and only two presented with multifocal haemorrhages. Most of the lung parenchyma was unaffected (Figures 5C, 5F, 5I, 5L, and 5O). The other changes were subacute, including mild hyperplasia of type II cells (four of six hamsters), and accumulation of hemosiderin-laden macrophages in four hamsters.

At the time of euthanasia, we also evaluated a series of hematological and serum chemistry parameters to test whether prime-boost vaccination could prevent any hematological changes upon infection of hamsters with SARS-CoV-2. All parameters were within normal limits and no clear trends emerged between vaccinated and control hamsters. Of note, NDV-GFP-vaccinated hamsters showed an elevated neutrophils count, and a higher neutrophil:lymphocyte ratio compared with those that were vaccinated with NDV-FLS, which has been correlated with disease severity in SARS-CoV-2-infected people (Karimi Shahri et al., 2020). This is consistent with the results of microscopic pathology, which showed numerous neutrophils into the lung of NDV-GFP-vaccinated hamsters.

**Vaccination of hamsters with NDV vectors expressing SARS-CoV-2 S decreases the magnitude of SARS-CoV-2 replication in tissues**

To evaluate the extent of virus replication in tissues, we quantified the presence of SARS-CoV-2 genomic RNA and infectious titers in the tissues of hamsters euthanized on day five pi. In the single-dose group, SARS-CoV-2 genome copy numbers were reduced significantly in the proximal and distal lungs of the NDV-FLS-treated group, while genome copies remained high in the hamsters treated with NDV-Δ19S and were not significantly different compared with controls (Figure 6A). Viral RNA levels in the nasal turbinates, small intestine, and blood did not differ between groups that received a single vaccine dose.
Similarly, a single dose of NDV-FLS significantly reduced the titers of infectious SARS-CoV-2 in the nasal turbinates, proximal, and distal lungs, compared with the NDV-GFP control. The NDV-Δ19S-vaccinated hamsters only had significantly reduced viral titers in the distal lung (Figure 6B). This may be due to some partial protection that prevented the spread of virus into the lower lung.

In animals receiving two vaccine doses, the NDV-FLS group had significantly reduced SARS-CoV-2 genome copies in all tissues examined, except for blood. While the NDV-Δ19S-vaccinated hamsters only had significantly reduced viral RNA levels in the small intestine (Figure 6C), there was a clear trend toward lower viral RNA levels in both the proximal and distal lung (Figure 6C). Hamsters in both prime-boost vaccine groups did not have any infectious virus in the lungs, and only two animals had low levels of virus in the nasal turbinates, suggesting protection of both the upper and lower airway is provided by two vaccine doses (Figure 6D).

We also examined SARS-CoV-2 mucosal shedding following infection with SARS-CoV-2, since a key question regarding the protective efficacy of vaccination and whether vaccination can effectively prevent virus transmission. Oral and rectal swabs were sampled day 2 pi to test whether vaccination may prevent acute virus shedding by these routes. Viral RNA was detected in oral and rectal swabs in all hamsters regardless of the vaccine regimen, without differences in the magnitude of shedding between groups (Figure S1A). Quantification of infectious titers in swabs showed that most hamsters shed at very low levels (<10^2 TCID_{50}/ml) in both groups, and no differences were observed in the magnitude of shedding (Figure S1B) or the proportion of shedding compared with non-shedding animals (Fisher’s exact test, data not show). This suggests that vaccination did not prevent infection and that virus shedding occurred in the early phases of infection, despite protection from disease. Whether the low levels of infectious virus in the oral and rectal swabs are sufficient to infect other hamsters is a question that remains to be answered.
Our data suggest that while vaccination prevented disease and significantly reduced viral growth in the tissues, infected animals may shed virus acutely after infection.

**Differential expression of immune response related genes in vaccinated hamsters**

To characterize the molecular drivers of inflammation and immune response in vaccinated and non-vaccinated hamsters, we examined the mRNA expression of various immune response-related genes (n = 11) in the lungs of hamsters in the prime-boost experimental groups, at day 5 pi. While several examined genes showed significant difference between vaccinated and control groups, only expression of interleukin (IL)-1β was significantly upregulated in both vaccine groups compared with the control (Figure S3). Vascular endothelial growth factor (VEGF) expression was the other and only gene to be upregulated in the NDV-FLS-treated group compared with the NDV-GFP control (Figure S3). The NDV-D19S-treated group showed differential expression of five additional genes compared with the NDV-GFP-treated control group: IL-6, FoxP3, IL-4, transforming growth factor (TGF)-β, and tumor necrosis factor alpha (TNF)-α (Figure S6). Upregulation of cytokine gene expression in vaccinated hamsters may account also for activation of the immune response, rather than tissue damage or inflammation, as pathology shows more severe lesions in the control (NDV-GFP) group.

We also examined relative expression levels of interferon gamma (IFN-γ) and IL-4 to attempt to determine whether a T helper type 1 (Th1) or Th2-associated bias in immune responses between groups may be driving susceptibility to infection. Both vaccine groups had higher, albeit not statistically significant, median IFN-γ:IL-4, ratios, and it is possible that inducing a Th1-associated immune response via vaccination may lead to improved infection outcomes (Jeyanathan et al., 2020).

**Lyophilized NDV-FLS retains its infectivity**

Given that hamsters vaccinated with NDV-FLS were protected from clinical signs and lesions following SARS-CoV-2 challenge, we sought to investigate whether it would be feasible to lyophilize this promising vaccine candidate thereby greatly simplifying its storage and distribution requirements. Aliquots of NDV-FLS stock containing the same number of PFU were adjusted to a final concentration of 5% sucrose, 5% sucrose/5% iodixanol, or mixed 1:1 with a solution containing 10% lactose, 2% peptone, 10mM Tris-HCl, pH 7.6, and lyophilized for 16h at -52°C. Two days later, samples were reconstituted in phosphate-buffered saline with 5% sucrose at the same volume and virus titer determined. As shown in Figure 7A, there was a ~2 fold loss of infectivity when NDV-FLS was lyophilized in 10% lactose, 2% peptone, 10mM Tris-HCl, pH 7.6 compared with virus frozen at -70°C. Further, as shown by Western blot analysis, the reconstituted vaccine preparation contained S protein at amounts comparable with the purified virus stock maintained at ultracold temperature, and was able to infect and induce expression of S protein in DF-1 cells (Figure 7B). Given the convenience and greatly simplified storage and transportation requirements of a lyophilized vaccine, further optimization of the lyophilization conditions, as well as assessment of retained efficacy in challenge experiments, is warranted for NDV-based vaccines against SARS-CoV-2.

**DISCUSSION**

The COVID-19 pandemic has seen an unprecedented number of vaccine candidates, with as many as 14 approved for use in at least one country (Organization). Given the evolution of novel variants of concern (Kirola, 2021; van Oosterhout et al., 2021), the likelihood of persistent spread of SARS-CoV-2 for several years (Scudellari, 2020), emerging data which suggest that the Delta variant may spread more readily than other SARS-CoV-2 variants among people vaccinated against COVID-19 (Brown et al., 2021; Musser et al., 2021; Riemersma et al., 2021), limitations in production capacity of developed vaccines (Khamsi, 2020), and the need for evidence of efficacy for multiple platforms moving forward, there will be a need for a diverse set of vaccine candidates to advance through all stages of development. Here we tested two live vaccine candidates based on an NDV vector expressing SARS-CoV-2 spike protein or a truncated version of the same protein in a hamster model to assess their potential for prevention of COVID-19.

The Syrian hamster has been used by our and other groups as a robust model for SARS-CoV-2 infection, and it is used to examine viral pathogenesis as well as testing vaccine efficacy (Griffin et al., 2021; Muñoz-Fontela et al., 2020). We vaccinated groups of ten hamsters with either NDV vaccine candidate, or NDV expressing GFP as a negative control. The vaccines were administered either as a single dose or as...
Figure 7. Lyophilized NDV-FLS virus retains infectivity

(A) Triplicate aliquots of equal numbers of NDV-FLS plaque-forming units (PFU) were either immediately frozen at −70°C or adjusted to a final concentration of 5% sucrose, 5% sucrose/5% Iodixanol, or mixed 1:1 with a stabilizing agent comprised of 10% lactose, 2% peptone, 10mM Tris-HCl, pH 7.6 and lyophilized at 44 x 10⁻³ MBAR and −52°C for 16 h. Lyophilized samples were stored at 4°C for 48 h before being resuspended in 1mL 5% sucrose/PBS and titered by mean tissue culture infectious dose (TCID₅₀) in DF-1 cells. Shown are data averages ± SD (n = 3/group). Statistical analysis was by one-way analysis of variance (ANOVA) with Tukey’s test for multiple comparisons. * = <0.05, ** = <0.01, *** = <0.001.

(B) The lyophilized and reconstituted NDV-FLS (10% lactose and 2% peptone preparation) contains similar levels of Spike (S) protein compared to the purified virus stored at −70°C, as assessed by Western blot analysis when equal amounts of virus are loaded on the gel (10⁷ PFU). Lyophilized and reconstituted NDV-FLS (10% lactose and 2% peptone preparation) expresses S protein in DF-1 cells at similar levels compared to NDV-FLS stored at −70°C, as assessed by Western blot of lysates from DF-1 infected with the same multiplicity of infection (MOI = 0.5).
two homologous doses 28 days apart. Both vaccines expressing SARS-CoV-2 S protein were immunogenic as assessed by ELISA for anti-SARS-CoV-2 IgG. Neither vaccine induced significantly high IgG titers after a single dose; however, following homologous booster immunization, both vaccine groups had significantly higher antibody titers compared with controls. When evaluating a prime-boost vaccination schedule, the vaccine expressing full-length S protein induced neutralizing antibody responses that were significantly greater than those seen in the group that received the vaccine with the truncated S protein. It is possible the low incorporation of the Δ19S into the NDV virion might have compromised an effective immune response due to lack of surface antigen presentation, despite the fact that NDV-Δ19S appeared to express higher amounts of S protein in vitro. Nonetheless, even the vaccine expressing the full-length S protein induced only modest PRNT90 titers, suggesting that efficacy to protect from clinical disease and microscopic pathology may not be entirely dependent upon the magnitude of neutralizing antibody titers. Similarly, hamsters in the prime-boost NDV-Δ19S group appeared to be nearly fully protected from SARS-CoV-2 replication in the lungs, where no infectious titers were evident, despite barely detectable neutralizing antibodies and modest IgG serum titers. It is possible that protection following vaccination with NDV may also rely on T cell responses, which might have been more strongly activated by the NDV-Δ19S vaccine, as it expresses higher level of S protein upon infection. However, this was not examined in our study due to a lack of appropriate reagents, such as hamster-specific antibodies for flow cytometry and depletion studies. Overall, these data suggest that some protection against disease and decreased viral replication can be afforded in the absence of high titers of neutralizing antibodies and further characterization of the immune responses generated by NDV-vectored vaccines, and others will be critical for enhanced immunization strategies.

Treatment with either NDV vaccine was able to decrease or eliminate SARS-CoV-2 replication in the lungs of infected hamsters. Hamsters that received a single vaccine dose had only modest reductions in viral loads in the upper and lower airways but vaccination with NDV-FLS afforded significant decrease in virus titers with only one dose. In the prime-boost cohort, aside from two hamsters with low levels of detectable virus in the nasal turbinates (NDV-Δ19S group), infectious virus could not be detected in the airways of vaccinated hamsters. Consistent with previous findings, there were still high levels of viral RNA in tissues of infected animals, even in the absence of detectable virus. This is likely due to detection of subgenomic mRNA, intermediates of genomic replication, or the presence of intact degraded non-viable viral particles in long-lived phagocytic cells such as macrophages and dendritic cells.

While vaccination with a prime-boost regimen induced near sterilizing immunity in the airways at day 5 pi, detection of viral RNA and infectious virus at day 2 pi in the oral and rectal swabs from all groups (i.e., regardless of regimen) suggests the possibility that vaccination does not eliminate viral shedding during the acute stages of infection. However, on day 5 pi, when we collected tissues rather than swabs, we did not detect any replicating virus in tissues that would lead to shedding suggesting that the vaccine prevented shedding at this time point. This is in line with evidence gathered from the ongoing vaccination campaign, showing that infection and shedding in vaccinated people does occur and is related to the levels of antibody titers in blood, despite still proving highly effective against clinical disease (Bergwerk et al., 2021; Brown et al., 2021). Nonetheless, our data show that vaccination with an NDV vector provides clear protection against SARS-CoV-2 replication and establishment in the airways and lungs.

In the monodose schedule, NDV-FLS-vaccinated hamsters had mildly decreased severity and distribution of microscopic lesions compared with the NDV-Δ19S- and NDV-GFP-treated groups, although differences with the latter were not statistically significant. These results agree with the findings of virus titration in organs, which showed that the vaccines administered as a monodose did not confer sterilizing immunity and still afforded virus replication. In the prime-boost schedule, the severity and extent of microscopic lesions stratified the treatment groups consistently with the magnitude of serum neutralizing antibodies and levels of SARS-CoV-2 replication in lungs. Hamsters vaccinated with NDV-FLS showed no to minimal lesions, some of which (i.e., epithelial hyperplasia and hemosiderophages) suggested that they were in the healing phase of the disease, without the presence of exudate. Hamsters treated with NDV-GFP showed the most severe lesions, characterized by presence of exudate in the alveoli and bronchioles. Finally, hamsters treated with NDV-Δ19S had lesions slightly less severe in extent and severity to those in the NDV-GFP group, albeit these differences were not statistically significant. Taken together, the pathology data indicate that NDV-FLS had a high protective effect against development of SARS-CoV-2-induced lesions, while NDV-Δ19S did so only partially.
Overall, the microscopic lesions caused by SARS-CoV-2 in the hamsters were consistent with the pathology documented elsewhere with this animal model (Chan et al., 2020a; Sia et al., 2020). The lesions observed in the control group (NDV-GFP) are also similar to what we observed in another pathogenesis study conducted by our team using untreated/naive hamsters (Griffin et al., 2021), indicating that the NDV backbone does not significantly affect the severity of SARS-CoV-2 infection in the lung. Lastly, development of hyaline membranes and marked fibrin exudation were not observed in our study. Although this is a typical feature of SARS-CoV-2 pathology in humans, this lesion has not been reported consistently in experimental settings (Gruber et al., 2020). Similarly, our model recapitulated development of vascular damage (i.e., endothelialitis); however no thrombosis was observed (Gruber et al., 2020).

The protection from pulmonary lesions reflects abated clinical signs, as shown by the overall and mean weight loss differences between vaccinated and control hamsters, especially in the single-dose group. In the prime-boost group, while NDV-FLS protected from acute weight loss at 5 dpi, the control group out-paced NDV-FLS-vaccinated hamsters at later time points, up to the end of the experiment (day 28 pi). This could be partly explained by sampling artifact, caused by euthanizing animals with greater clinical signs first, and leaving less affected hamsters for long-term weight assessment. Alternatively, it is possible that hamster suffering a more severe disease (i.e., control group) may undergo a compensatory weight gain phase. This has been also observed by our group in a recent COVID-19 pathogenesis study that used a similar hamster model (Griffin et al., 2021).

Findings from the vaccination experiment unquestionably show that NDV-FLS is superior to NDV-Δ19S as a vaccine candidate against COVID-19. This suggests that incorporation of the vaccine antigen within the envelope of the NDV virion is necessary to trigger an effective immune response, possibly by direct interaction with B cell receptors as a prerequisite for induction of antibody responses (Heesters et al., 2016). While NDV-Δ19S-infected cells expressed higher levels of S protein compared with NDV-FLS-infected cells, the truncated S protein was poorly incorporated in the NDV envelope, as shown by Western blot analysis of purified vaccine preparations. While truncation of the 19 carboxy-terminal amino acids of the S protein has been shown to increase envelope incorporation in other viruses, such as VSV and lentiviral particles (Duan et al., 2020), this was not the case for NDV. This occurrence may be caused by a spatial mismatch between localization of the truncated S protein on the plasma membrane and specific sites of NDV release, which are cholesterol-rich sites defined as lipid rafts (Laliberte et al., 2006). Alternatively, truncation of the S protein may have led to inappropriate interaction with the NDV matrix (M) protein, which binds electrostatically with the NDV surface glycoproteins and drives budding of mature virions (Battisti et al., 2012; García-Sastre et al., 1989). This finding indicates that decoration of the vaccine envelope with the antigen of interest can improve the efficacy of vaccination, and further suggests that for development of NDV-based vaccine platforms, foreign surface epitopes should be chimerized with the transmembrane and cytoplasmic domains of NDV surface proteins (Sun et al., 2020a).

Several biomarkers of disease have been defined in COVID-19 patients, including changes in the concentration of cells in blood and in the presence of various cytokines and vascular growth factors (Karimi Shahri et al., 2020). In this study, we examined whether any significant hematological or serum chemistry changes could be detected and whether these might be indicative of disease progression, compared with protection against disease in prime-boost vaccinated animals. We detected elevated neutrophil counts as well as neutrophil:lymphocyte ratios in the blood of control hamsters, which have been linked to more severe disease progression (Li et al., 2020b). Specifically, neutrophilia appears to be induced by inflammatory mediators produced in diseased tissues, such as lung, and lymphopenia is a typical feature of acute viral infection, such as SARS-CoV-2 (Frater et al., 2020; Karimi Shahri et al., 2020). In the NDV-GFP-treated group, numerous neutrophils were recruited in the areas of affected lung, suggesting that neutrophilia was needed to satisfy peripheral tissue demands during infection. Elevated hemoglobin levels seen in control hamsters could also indicate some level of pulmonary distress and greater need for oxygen throughout the body, although in human patients low levels of hemoglobin appear to be associated with a poor outcome (Karimi Shahri et al., 2020). While some differences were seen in serum biomarkers such as glucose, urea nitrogen, and calcium, along with the above-mentioned changes in hematological markers, it is not possible to interpret the kinetics of these parameters with only one data point available.

Acute SARS-CoV-2 infection in hamsters lasts about one week, with a peak of infection between days two and four, therefore critical questions regarding viral replication and the immune responses generated may require...
examination of animals euthanized at multiple time points. Accordingly, our examination of differentially expressed immune-related genes at day 5 pi represents a snapshot of one time point. Overall, our data show a trend by which cytokines appear to be more expressed in the lungs of vaccinated and challenged hamsters, compared to the control group, possibly as an effect of immune response activation. These differences appear to be more obvious in the NDV-Δ19S-vaccinated group, and may reflect the high levels of S protein expression seen in vitro. Conceivably, production of large amounts of intracellular foreign epitope may have triggered a more robust cell-mediated response compared to NDV-FLS, which induces lower S protein expression in vitro despite incorporating more S protein onto the envelope. Depletion studies could help define the contribution of cell-mediated and humoral response in the immunity elicited by our vaccines, however, lack of suitable reagents in hamsters limited our study to examining antibody responses and cytokine gene expression levels. Further characterization of immune responses and protective efficacy of NDV vaccines in other models such as mice or non-human primates may provide further insights into what immunological effector mechanisms are induced by vaccination with NDV and how these play a role in protection from disease.

Recombinant NDV vaccine platforms provide an option that has proven to be safe and immunogenic in several studies (Bukreyev et al., 2005; DiNapoli et al., 2007, 2010; Kim and Samal, 2016), and here is shown to provide full protection in a hamster model of COVID-19. Overall, the vaccines tested in this study were safe in hamsters, and expression of the S protein did not appear to change the virulence of the backbone. The vaccines were lentogenic (i.e., non-virulent) in chicken eggs, consistent with a non-virulent fusion cleavage site of the NDV fusion protein (Cattoli et al., 2011), and were not neutralized by S protein-specific serum, suggesting that the S protein did not contribute to infectivity of NDV recombinants. Moreover, lyophilization of the NDV-FLS vaccine did not substantially reduce virus titer and maintained its ability to infect cells and express the S protein. Although these are attractive analytical qualities, the lyophilized and reconstituted NDV-FLS should be further tested in vaccination/challenge studies, to conclusively demonstrate retained immunogenicity upon lyophilization.

Despite having substantial incorporation of S protein in the envelope, NDV-FLS had lower fusogenic activity compared with NDV-Δ19S or NDV-GFP. The higher fusogenicity of NDV-Δ19S compared with NDV-FLS is likely mediated by the higher expression of truncated spike protein, as seen in DF-1 cells, and its increased localization on the plasma membrane, due to lack of the Golgi anchoring signal (Boson et al., 2021). Nonetheless, the ability of NDV-Δ19S to develop syncytia was similar to what observed with NDV-GFP, and did not increase virulence for embryonated eggs.

Recently, a live attenuated NDV vaccine against COVID-19 has been developed by another group. This vaccine was engineered to express either a wild-type spike protein, or a stabilized version that does not undergo cleavage (pre-fusion stabilized) (Sun et al., 2020a). Upon intramuscular delivery using 10–50 μg of purified virus preparation (virus was not quantified by an infectivity assay) in a homologous prime-boost schedule 21 days apart, both vaccines induced neutralizing antibody and completely inhibited replication of a mouse-adapted SARS-CoV-2 strain in the lungs of BALB/c mice. While this is similar to what was observed with our NDV-FLS prime-boost group, it should be noted that in mice, titers of SARS-CoV-2 in lung tissues peaked at approximately 10⁴ PFU/lung lobe, as opposed to titers of up to 10⁷ TCID₅₀/g of lung in the control hamsters of our study. Similarly, mice did not develop clinical signs or microscopic lesions, preventing assessment of protection against clinical signs or tissue damage (Sun et al., 2020a). An inactivated version of the same vaccine (10 μg alone or 5 μg with adjuvant) was also administered intramuscularly in an homologous prime-boost regimen, and it protected both mice and hamsters from virus replication in lung tissues at day 5 pi; however, microscopic lung pathology was not assessed in this research (Sun et al., 2020b). While these studies support the notion that NDV is a successful and versatile vaccine platform against SARS-CoV-2, differences regarding vaccine type (inactivated vs. infectious), delivery (intranasal vs. intramuscular), dose assessment (mass vs. infectivity), and type of animal model prevent a direct comparison with our results.

As NDV is a respiratory virus, in our vaccine trial we opted to deliver NDV intranasally, as already successfully attempted in other studies (Bukreyev et al., 2005; DiNapoli et al., 2007, 2010). Activation of the local mucosa-associated lymphoid tissue has the potential to markedly decrease nasal shedding of the virus (Gal et al., 2021), which is of paramount importance to curtail circulation of SARS-CoV-2 in a partially immune population, and therefore limit the development of vaccine escape variants. Notably, in mice, complete protection against SARS-CoV-1 challenge is afforded only upon intranasal, but not subcutaneous, vaccine administration.
(Zhao et al., 2016). Although in our study we did not test development of SARS-CoV-2-specific mucosal immunity due to lack of reagents, in the prime-boost schedule NDV-FLS-treated hamsters had no detectable infectious SARS-CoV-2 in the turbinates or the upper and lower lungs day 5 pi, suggesting development of sterilizing immunity. However, considering that low-level shedding of infectious virus was observed at day 2 pi even in vaccinated groups, vaccination may not protect against the early phases of SARS-CoV-2 replication. It is unclear if such low amounts of infectious virus would be able to infect other animals, or even if the detected virus may – at least in part – represent left-over inoculum. Lastly, as the prime-boost group in our study showed a clear increase of S-specific antibodies after the second dose, it is likely that immunity against the vector backbone did not impact the efficacy of a booster shot.

Many COVID-19 vaccine candidates are in various stages of clinical development, with some currently being given emergency-use approval in several countries. However, due to the relative advantages and disadvantages of different vaccine platforms, there is an ongoing need to develop and test novel vaccine platforms and strategies. This will also be critical in the case of potential future pandemics and emerging and re-emerging infections, which will require swift development of vaccine candidates. The prospect of having several different platforms available for rapid development should a novel pathogen arise is of critical importance. Live viral vectors are particularly advantageous due to their generally high immunogenicity, ability to induce both humoral and cellular immune responses, and the lack of a need for adjuvants (Vrba et al., 2020). This work provides evidence that this platform can provide substantial protection against SARS-CoV-2 infection and could be a viable option for further clinical development.

Limitations of the study
Oral and rectal swabs were taken on day two post-challenge with SARS-CoV-2 primarily to confirm viral replication in our hamster infection model; therefore, we did not take swabs on day five post-challenge. As these swabs were taken at such an acute time point, we cannot know for certain whether the virus or RNA detected was from leftover inoculum, at least in the oral swabs. Additionally, although the vaccine was administered to hamsters intranasally, the method of administration used would have resulted in vaccine reaching the distal lungs, where it could potentially replicate. To evaluate the true potential of intranasal administration of an NDV-based COVID-19 vaccine, a larger animal model such as a sheep, in which the efficacy of intranasal administration could be evaluated separate from pulmonary administration, would be required. Indeed, large animal studies to address efficacy of intranasal vs. pulmonary administration are currently ongoing.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Ethics statement
  - Cells
- **METHODDETAILS**
  - Engineering and rescue of recombinant NDV vaccines
  - Challenge virus and vaccine candidates
  - Immunofluorescence assay and titration of recombinant NDV vaccines
  - Vaccine characterization in DF-1 cells
  - Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot analysis
  - Neutralization of pseudotyped lentiviruses and NDV recombinant vaccines
  - Determination of mean death time (MDT)
  - Lyophilization of NDV-FLS
  - Immunization and infection of Syrian hamsters
  - Microscopic pathology
  - Detection of SARS-CoV-2 RNA in tissues and swabs of infected hamsters
  - Detection of infectious SARS-CoV-2 in tissues and swabs of infected hamsters
  - Determination of antibody responses by ELISA and PRNT assay
Hematological and biochemical analysis of blood and serum
Cytokine mRNA analysis

QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.103219.

ACKNOWLEDGMENTS
This work was funded by an Ontario Ministry of Colleges and Universities COVID-19 Rapid Research Fund project grant to BWB, SKW, LS and DK (C-018-2415020-BRIDLE), the University of Guelph COVID-19 Research Development and Catalyst Fund granted to BWB, SKW, and LS, Natural Sciences and Engineering Research Council of Canada Discovery Grants to SKW (grant # 304737), LS (grant #401127) and BWB (grant #436264) and the Canadian Scientific Research and Experimental Development (SRED) program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All work performed at the National Microbiology Laboratory was supported by the Public Health Agency of Canada.

AUTHOR CONTRIBUTIONS
Conceptualization, S.K.W., L.S., B.W.B, P.P.M., D.K., B.M.W.; methodology, S.K.W., L.S., B.W.B., B.D.G., B.M.W., and D.K.; animal experiments (including vaccination, challenge, virus titration, and serology), B.M.W, M.C., R.V., N.T., E.V., A.L., S.H., B.D.G., J.A., M.H., K.T., A.A., K.L.F., and D.K.; R.C.M, LC, Y.M., J.P.K., and J.A.M.; writing – original draft, B.M.W., S.K.W., L.S., and D.K.; funding acquisition and resources, B.W.B., S.K.W., L.S., and D.K.; supervision, S.K.W., L.S., B.W.B, D.K., L.B., D.S., H.W., and S.B.

DECLARATION OF INTERESTS
L.A.S., Y.P., B.W.B., P.P.M., L.S., and S.K.W. are co-inventors on a United States Provisional Application No. 63/196,489 entitled “ENGINEERED NEWCASTLE DISEASE VIRUS VECTOR AND USES THEREOF”, which was filed June 3, 2021.

INCLUSION AND DIVERSITY
We worked to ensure sex balance in the selection of non-human subjects. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science. One or more of the authors of this paper self-identifies as a member of the LGBTQ+ community. One or more of the authors of this paper self-identifies as living with a disability. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list.

Received: May 7, 2021
Revised: August 24, 2021
Accepted: September 30, 2021
Published: November 19, 2021

REFERENCES
Afonso, C.L. (2008). Not so fast on recombination analysis of Newcastle disease virus. J. Virol. 82, 9303. https://doi.org/10.1128/JVI.01231-08.

Andersen, K.G., Rambaut, A., Lipkin, W.I., Holmes, E.C., and Garry, R.F. (2020). The proximal origin of SARS-CoV-2. Nat. Med. 26, 450–452. https://doi.org/10.1038/s41591-020-0820-9.

Battisti, A.J., Meng, G., Winkler, D.C., McGinness, L.W., Plevka, P., Steven, A.C., Morrison, T.G., and Rossmann, M.G. (2012). Structure and assembly of a paramyxovirus matrix protein. Proc. Natl. Acad. Sci. U S A 109, 13996–14000. https://doi.org/10.1073/pnas.1210275109.

Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipstich, M., Cohen, C., Mandelboim, M., Gal Levin, E., Rubin, C., Indenbaum, V., et al. (2021). Covid-19 breakthrough infections in vaccinated health Care workers. N. Engl. J. Med. https://doi.org/10.1056/NEJMoaa2109072.

Besutti, G., Bonacini, R., Iotti, V., Marini, G., Riva, N., Dolci, G., Maieron, M., Spaggiari, L., Monelli, F., Ligabue, G., et al. (2020). Abdominal visceral infarction in 3 patients with COVID-19. Emerg. Infect. Dis. 26, 1926–1928. https://doi.org/10.3201/eid2608.201161.

Boson, B., Legros, V., Zhou, B., Siret, E., Mathieu, C., Cosset, F.L., Lavillette, D., and Denollet, S. (2021). The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles. J. Biol. Chem. 296, 100111. https://doi.org/10.1074/jbc.RA120.016175.

Bradley, B.T., Maioli, H., and Johnston, R. (2020). Histopathology and ultrastructural findings of...
fatal COVID-19 infections in Washington State: a case series (vol 396, pg 520, 2000). Lancet 396, 312.

Brown, C.M., Vostok, J., Johnson, H., Burns, M., Gharpure, R., Sami, S., Sabo, R.T., Hall, N., Foreman, A., Schubert, P.L., et al. (2021). Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings - Barnstable County, Massachusetts, July 2021. MMWR Morb. Mortal. Wkly. Rep. 70, 1059–1062. https://doi.org/10.15585/mmwr.mm7031e2.

Bukreyev, A., Huang, Z., Yang, L., Elankumaran, S., St. Claire, M., Murphy, B.R., Samal, S.K., and Collins, P.L. (2005). Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J. Virol. 79, 13275–13284. https://doi.org/10.1128/JVI.79.21.13275-13284.2005.

Calabrese, F., Pezzuto, F., Fortezza, H., Hofman, P., Kern, I., Panizo, A., van der Thesen, J., Timofeev, S., Gorkiewicz, G., and Lunardi, F. (2020). Pulmonary/wynusalb group and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists. Virchows Arch. https://doi.org/10.1007/s00428-020-02886-6.

Calzas, C., and Chevalier, C. (2019). Innovative mucosal vaccine formulations against influenza A virus infections. Front. Immunol. 10, 1605. https://doi.org/10.3389/fimmu.2019.01605.

Capua, I., and Alexander, D.J. (2004). Human health implications of avian influenza viruses and paramyxoviruses. Eur. J. Clin. Microbiol. Infect. Dis. 23, 1–6. https://doi.org/10.1007/s10096-003-1059-3.

Cattoli, G., Susta, L., Terregino, C., and Brown, C. (2011). Newcastle disease: a review of field recognition and current methods of laboratory detection. J. Vet. Diagn. Invest. 23, 637–656. https://doi.org/10.1177/1040638711407887.

Chan, J.F., Zhang, A.J., Yuan, S., Poon, V.K., Chan, C.C., Lee, A.C., Chan, W.M., Fan, Z., Tsoi, H.W., Wong, L., et al. (2020). Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. 71, 2428–2446. https://doi.org/10.1093/cid/ciaa325.

Chan, J.F.W., Yuan, S.F., Kok, K.H., To, K.K.W., Chu, H., Yang, J., Xing, F.F., Liu, J.L., Yip, C.C.Y., Poon, R.W.S., et al. (2020b). A familial cluster of respiratory illness in a golden Syrian hamster model of SARS-CoV-2 infection. bioRxiv, 448196. https://doi.org/10.1101/2020.07.25.221291.

Griffin, B.D., Warner, B.M., Duggan, A.T., Moffat, E., He, S., Garnett, L., et al. (2020). North American Deer Mice Are Susceptible to SARS-CoV-2. bioRxiv. 2020.2007.2025.221291. https://doi.org/10.1101/2020.07.25.221291.

Griffin, B.D., Warner, B.M., Chan, M., Mendoza, E.J., Tailor, N., and Ritter, D.G. (2020). Optimized pseudotyping conditions for the SARS-CoV-2 spike glycoprotein. J. Virol. 94. https://doi.org/10.1128/JVI.01062-20.

Kandel, A., Bagato, O., Zaraket, H., Debeuchamp, J., Krauss, S., El-Shesheny, R., Webbby, R.J., Ali, M.A., and Kayali, G. (2014). Proteolytic enzymes in embryonated chicken eggs sustain the replication of egg-grown low-pathogenicity avian influenza viruses in cells in the absence of exogenous proteases. J. Virol. Methods 202, 28–33. https://doi.org/10.1016/j.jviromet.2014.02.023.

Karadag, E. (2020). Increase in COVID-19 cases and case-fatality and case-recovery rates in Europe: a cross-temporal meta-analysis. J. Med. Virol. 92, 1511–1517. https://doi.org/10.1002/jmv.26035.

Karder, G. (1931). Beitrag zur kollektivenbehandlung pharmakologischer reihenversuche. Archiv fur Experimentelle Pathologie und Pharmakologie 162, 480–483.

Karim Shahn, M., Niazkar, H.R., and Rad, F. (2020). COVID-19 and hematology findings based on the current evidences: a puzzle with many missing pieces. Int. J. Lab Hematol. https://doi.org/10.1111/ijlh.13554.
particles. J. Virol. and release of infectious Newcastle disease virus lipid rafts is necessary for the ordered assembly and Morrison, T.G. (2006). Integrity of membrane Laliberte, J.P., McGinnes, L.W., Peeples, M.E., surfaces, environmental, and personal protective equipment contamination by severe acute pathogenesis and transmission of SARS-CoV-2 in Newcastle disease virus (NDV) expressing the van Oosterhout, C., Hall, N., Ly, H., and Tyler, F. (2020). Predictive values of severe respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA 323, 1610–1612. https://doi.org/10.1001/jama.2020.3227. van Oosterhout, C., Hall, N., Ly, H., and Tyler, K.M. (2021). COVID-19 evolution during the pandemic - implications of new SARS-CoV-2 variants on disease control and public health policies. Virulence 12, 507–508. https://doi.org/10.1080/21505594.2021.1877066. Organization, W.H. (n.d) Draft Landscape and Tracker of COVID-19 Candidate Vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Ou, X., Liu, Y., Lei, X., Li, P., M., D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620. https://doi.org/10.1038/s41467-020-15562-9. Park, M.S., Steel, J., Garcia-Sastre, A., Swaye, D., and Palese, P. (2008). Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc. Natl. Acad. Sci. U S A 105, 8203–8208. https://doi.org/10.1073/pnas.0602561103. Pecora, A.L., Ruvi, N., Cohen, G.I., Meropol, N.J., Sterman, D., Marshall, J.L., Goldberg, S., Gross, P., O’Neil, J.D., Groene, W.S., et al. (2002). Phase I trial of intravenous administration of PV01, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20, 2251–2266. https://doi.org/10.1200/JCO.2002.0084. Peiris, M., and Leung, G.M. (2020). What can we expect from first-generation COVID-19 vaccines? Lancet 396, 1467–1469. https://doi.org/10.1016/S0140-6736(20)30251-8. Sun, W., Leist, S.R., McCroskery, S., Liu, Y., Slamang, S., Oliva, J., Amanat, F., Schafer, A., Dinnon, K.H., Garcia-Sastre, A., et al. (2020a). Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live vaccine candidate. EBioMedicine 62, 103132. https://doi.org/10.1016/j.ebiom.2020.10.008. Sun, W., McCroskery, S., Liu, W.C., Leist, S.R., Liu, Y., Albrecht, R.A., Slamang, S., Oliva, J., Amanat, F., Schafer, A., et al. (2020b). A Newcastle disease virus (NDV) expressing a membrane-anchored inactivated SARS-CoV-2 vaccine. Vaccines (Basel) 8. https://doi.org/10.3390/vaccines8040771. Varga, Z., Flammer, A.J., Steiger, P., Haberecker, M., Anders, R., Zinkernagel, A.S., Mehra, M.R., Schuepbach, R.A., Ruschitzka, F., and Moch, H. (2020). Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417-1418. https://doi.org/10.1016/S0140-6736(20)30937-5. Verity, R., Okell, L.C., Dorigatti, I., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P.G. T., and Hu, et. al. (2020). Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect. Dis. 20, 649–657. https://doi.org/10.1016/S1473-3099(20)30243-7. Vrba, S.M., Kirk, N.M., Brisse, M.E., Liang, Y., and Ly, H. (2020). Development and applications of
viral vectored vaccines to combat zoonotic and emerging public health threats. Vaccines 8 https://doi.org/10.3390/vaccines8040680.

Warner, B.M., Safronetz, D., and Kobinger, G.P. (2017). Syrian hamsters as a small animal model for emerging infectious diseases: advances in immunologic methods. Adv. Exp. Med. Biol. 972, 87–101. https://doi.org/10.1007/978-0-387-80680-3_5.

Wheelock, E.F., and Dingle, J.H. (1964). Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report. N. Engl. J. Med. 271, 645–651. https://doi.org/10.1056/NEJM196409242711302.

WHO, (n.d.) (Last accessed 2020.09.07). WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int.

Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., Curtis, H.J., Mehrkar, A., Evans, D., Ingleby, P., et al. (2020). Factors associated with COVID-19-related death using OpenSAFELY. Nature. https://doi.org/10.1038/s41586-020-2521-4.

Zhao, W., Zhang, Z., Zsak, L., and Yu, Q. (2015). P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression. J. Gen. Virol. 96, 40–45. https://doi.org/10.1099/vir.0.068437-0.

Zhao, J., Zhao, J., Mangalam, A.K., Channappanavar, R., Fett, C., Meyerholz, D.K., Agnihotram, S., Baric, R.S., David, C.S., and Perlman, S. (2016). Airway memory CD4\(^{+}\) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity 44, 1379–1391. https://doi.org/10.1016/j.immuni.2016.05.006.

Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273. https://doi.org/10.1038/s41586-020-2012-7.

Ziegler, C.G.K., Allon, S.J., Nyquist, S.K., Mbano, I.M., Mao, V.N., Tsouanas, C.N., Cao, Y.M., Yousif, A.S., Bals, J., Hauser, B.M., et al. (2020). SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181, 1016. https://doi.org/10.1016/j.cell.2020.04.035.

El Zowalaty, M.E., and Jarhult, J.D. (2020). From SARS to COVID-19: a previously unknown SARS-related coronavirus (SARS-CoV-2) of pandemic potential infecting humans - call for a One Health approach. One Health 9, 100124. https://doi.org/10.1016/j.onehlt.2020.100124.
### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Mouse anti-NDV ribonucleoprotein | Novus Biologicals | NBP2-11633 |
| Goat anti-Mouse IgG conjugated to Alexa Fluor 488 | ThermoFisher | Cat# A-11001; RRID:AB_2534069 |
| Rabbit anti-SARS-CoV-2 nucleocapsid | ThermoFisher | Cat# PAS-81794; RRID:AB_2788968 |
| Rabbit anti-SARS-CoV-2 S1 | ThermoFisher | Cat# PAS-81795; RRID:AB_2788969 |
| Rabbit anti-SARS-CoV-2 S2 | Novus Biologicals | Cat# NB100-56578; RRID:AB_838846 |
| Mouse anti-beta actin | ThermoFisher | Cat# MAS-15739; RRID:AB_10979409 |
| Goat anti-rabbit IgG conjugated to horseradish peroxidase | ThermoFisher | Cat# G-21234; RRID:AB_2536530 |
| Goat anti-mouse IgG conjugated to horseradish peroxidase | ThermoFisher | Cat# G-21040; RRID:AB_2536527 |
| Goat anti-hamster IgG (H+L) conjugated to horseradish peroxidase | KPL | S220-0371 |
| **Bacterial and virus strains** |        |            |
| NEB® Stable Competent E. coli (High Efficiency) | New England Biolabs | C3040I |
| SARS-CoV-2; hCoV-19/Canada/ON-VIDO-01/2020, GISAID accession# | Sunnybrook Research Institute | NA |
| EPI_ISL_425177 | University of Guelph | NA |
| NDV-FLS | University of Guelph | NA |
| NDV-Δ19S | University of Guelph | NA |
| NDV-GFP | University of Guelph | NA |
| **Chemicals, peptides, and recombinant proteins** |        |            |
| 2.5% Trypsin (10X) | ThermoFisher | 15090-046 |
| Protease inhibitor cocktail | ThermoFisher | 0087785 |
| Pierce SuperSignal West Pico PLUS Chemiluminescent Substrate | ThermoFisher | 34580 |
| L-poly-L-lysine | Millipore Sigma | P4707 |
| Iodixanol (OptiPrep™ Density Gradient Medium) | Millipore Sigma | D1556 |
| Lactose | Millipore Sigma | 17814 |
| Peptone | Millipore Sigma | P6838 |
| SARS-CoV-2 (2019-n-CoV) Spike protein (S1+S2 ECD, His Tag) | Sino Biological | 40589-V08B1 |
| SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein | Sino Biological | 40588-V08B |
| 1 Step Ultra TMB-ELISA substrate | ThermoFisher | 34028 |
| Carboxymethylcellulose | Millipore Sigma | C5678 |
| Crystal Violet, 0.5% Solution | Fisher | S25275B |
| 10% neutral-buffered formalin | Fisher | 22-220682 |
| **Critical commercial assays** |        |            |
| Pierce BCA Protein Assay Kit | ThermoFisher | 23225 |
| Pierce Firefly luciferase Glow Assay Kit | ThermoFisher | 16176 |
| QIAamp Viral RNA mini kit | Qiagen | 52906 |
| RLT Buffer | Qiagen | 79216 |
| RNasey Plus Mini kit | Qiagen | 74134 |
| TaqPath 1-Step Multiplex Master Mix kit | ThermoFisher | A28525 |
| **Experimental models: Cell lines** |        |            |
| Vero | ATCC | CCL-81 |
| Vero E6 | ATCC | CRL-1586 |

(Continued on next page)
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dr. Sarah Wootton, University of Guelph (kwootton@uoguelph.ca).

Materials availability
Plasmids generated in this study are available upon request following execution of a material transfer agreement (MTA).

Data and code availability
- All data reported in this paper will be shared by the lead contact upon request.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ethics statement
The animal experiments described were carried out at the National Microbiology Laboratory (NML) of the Public Health Agency of Canada. Studies were approved by the Animal Care Committee at the Canadian Science Center for Human and Animal Health in accordance with the guidelines provided by the Canadian Council on Animal Care. All procedures including vaccinations, infections, swabs, collections were
performed under anesthesia, and all efforts were made to minimize animal suffering and to reduce the number of animals used. All SARS-CoV-2 infectious work was performed under containment level 4 (CL-4) conditions. Equal numbers of male and female hamsters four to six weeks of age were monitored daily for any adverse signs following vaccinations and infections, and were provided food and water *ad libitum*.

**Cells**

Vero (ATCC CCL-81) and Vero E6 (CRL-1586) cells were maintained in Minimum Essential Media (MEM) (Thermo Fisher Scientific, USA) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich). DF-1 cells (ATCC CRL-12203) were maintained in DMEM supplemented with 10% bovine calf serum (BCS). HEK293-hACE2 cells grown on tissue culture plates coated with L-poly-L-lysine and maintained in DMEM supplemented with 10% FBS.

**METHOD DETAILS**

**Engineering and rescue of recombinant NDV vaccines**

The full-length cDNA genome of lentogenic NDV LaSota strain was designed based on Genbank accession AF077761.1 to contain a GFP reporter gene and essential NDV-specific RNA transcriptional signals, flanked by a 5’ XbaI site and a 3’ MluI site at nucleotide position 3143 between the P and M genes. A leucine-to-alanine mutation at position 289 was also introduced into the fusion gene. The full-length recombinant clone was synthesized *de novo* using a synthesis service (GeneArt, ThermoFisher). To construct recombinant NDV expressing SARS-CoV-2 Spike, forward 5’GCACCGAGTTCCCCCTTAGATTAGAAAAATACGGGTAGAACGCCGCAC-3’ and reverse 5’GTTGGACCTTGGGTACGCGTTTATCATCAGCAAGAGCCGCAAGAACAC-3’ primers were used to amplify human codon optimized SARS-CoV-2 full-length spike. Additionally, a 19 amino acid-truncated form of the S protein (SΔ19) was amplified using the previous forward primer and a reverse 5’GTTGGACCTTGGGTACGCGTTTATCATCAGCAAGAGCCGCAAGAACAC-3’.

**Challenge virus and vaccine candidates**

The SARS-CoV-2 used in this study (SARS-CoV-2; hCoV-19/Canada/ON-VIDO-01/2020, GISAID accession# EPI_ISL_425177) was isolated from a clinical specimen at Sunnybrook Research Institute (SRI)/ University of Toronto on VeroE6 cells and provided to us by the Vaccine and Infectious Disease Organization (VIDO) with permission. The virus was grown in Vero cells (ATCC, CCL-81) in minimum essential medium (Hyclone) containing 1% fetal bovine serum (FBS) and 1% L-glutamine, and a passage 2 (P2) virus stock was used for all infections. The virus was titrated on Vero cells by conventional limiting dilution assays and reported as TCID50, as described previously (Griffin et al., 2020).

**Immunofluorescence assay and titration of recombinant NDV vaccines**

NDV vaccine stocks were titered on DF-1 cells (immortalized chicken embryo fibroblasts [ATCC CRL-12203]) by immunofluorescence (IFA) assay. Cells were plated in 96-well plates (4x10⁴ cells / well) in DMEM supplemented with 2% bovine calf serum (BCS) and 5% allantoic fluid, left to adhere overnight, and infected the next day with serial 10-fold dilutions of purified allantoic fluid containing recombinant NDV vaccine. Approximately 24 hr post-infection, cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature (RT), and permeabilized in 0.1% NP-40 for 10 minutes at RT. Antigens were masked in blocking buffer [5% (v/v) normal goat serum in PBS-T] either for one hour at RT or overnight at 4°C, followed by incubation with a primary mouse anti-NDV ribonucleoprotein (NBP2-11633, monoclonal; Novus Biologicals) diluted 1:2000 in blocking buffer (one hour at RT or overnight at 4°C). The secondary antibody was a goat-anti-mouse conjugated with Alexa Fluor 488 (A-11001, ThermoFisher) diluted 1:1000, which was applied in PBS-T for one hour at RT in the dark. Cells were imaged using an Axio Observer inverted...
fluorescent microscope. For titration, positive wells per dilution were tallied and titer reported as TCID<sub>50</sub>/mL, according to the Spearman-Karber method (Karber, 1931).

**Vaccine characterization in DF-1 cells**

DF-1 cells were seeded into 6-well plates at 1.5x10<sup>6</sup> cells/well in 1 mL of DMEM with 2% bovine calf serum and supplemented with 5% allantoic fluid or 100 µg/ml of trypsin (ThermoFisher), to provide proteolytic activity. After adherence, cells were infected with either NDV-FLS, NDV-Δ19S or NDV-GFP at a multiplicity of infection (MOI) of 1 or 10 in replicate plates and incubated at 37°C. Approximately 24 hours after infection, plates were observed under an inverted phase contrast microscope to examine and document cytopathic effect. Subsequently, one set of replicate plates was used for IFA as described above, and another was used for protein extraction and western blot analysis (see below).

**Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot analysis**

DF-1 cells were infected in 6-well plates as described above (MOI = 1), washed with PBS and lysed for 30 min in radioimmunoprecipitation assay buffer [50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1X protease inhibitor cocktail (0087785, ThermoFisher)]. Cell lysates were centrifuged at 10,000 xg for 15 min at 4°C, supernatants collected and used to quantify the protein concentration using the Pierce BCA Protein Assay Kit (ThermoFisher). For SDS-PAGE, purified virus (1x10<sup>7</sup> PFU) or virus infected cell lysates (mixed with 6x loading dye containing and 30% β-mercaptoethanol) were heated at 95°C for 10 min to denature proteins, followed by cooling on ice. The same PFU or protein amounts of each sample (ranging from 5 to 70 µg depending on the experiment) were loaded into wells of 4% stacking / 12% resolving gels, and proteins were resolved at 120 V for 1.5 h in running buffer (0.025 mM Tris-base, 0.192 M glycine, 0.1% SDS). Proteins were transferred to a 0.2 µm polyvinylidene fluoride or polyvinylidene difluoride (PVDF) membrane for 30 min, using the BioRad Trans-Blot Turbo Trans-Blot Turbo System and associated buffer (BioRad Trans-Blot Turbo RTA Mini PVDF Transfer Kit). Following transfer, the rest of the protocol was performed as previously described (Pham et al., 2020). Briefly, the primary antibodies were incubated overnight at 4°C, and were either mouse anti-NDV ribonucleoprotein (dilution: 1:5000; NB2-11633; Novus Biologicals), rabbit anti-SARS-CoV-2 nucleocapsid (dilution: 1:5000; PA5-81794; ThermoFisher), rabbit anti-SARS-CoV-2 S1 (dilution: 1:1000; PA5-81795; ThermoFisher) or S2 (dilution: 1:1000; NB100-56578; Novus Biologicals) subunits, or mouse anti-beta actin (diluted 1:1000; MA5-15739; ThermoFisher). The secondary antibodies were either goat anti-rabbit (G-21234) or goat anti-mouse IgG (G-21040) conjugated to horseradish peroxidase (diluted 1:2000; ThermoFisher), and incubated for 1 to 3 h at RT. Protein was detected using the Pierce SuperSignal West Pico PLUS Chemiluminescent Substrate (ThermoFisher) and the BioRad ChemiDoc MP Imaging System (BioRad Image Lab 6.0.1. software).

**Neutralization of pseudotyped lentiviruses and NDV recombinant vaccines**

To evaluate the contribution of the S protein to the infectivity of NDV-FLS and NDV-Δ19S, neutralization assays were conducted using immune chicken serum against NDV and murine serum raised against the S protein (see below). The chicken serum was collected from routinely vaccinated White Leghorn hens (Arkell Research Station, University of Guelph).

Briefly, mice were vaccinated intramuscularly with 10<sup>5</sup> infectious units (IU) of adenovirus expressing FLS, in an homologous prime-boost regimen 28 days apart. The neutralizing activity of the serum was tested on lentiviral particles pseudotyped with the truncated version of the S protein (Δ19S) and encoding the luciferase gene. Neutralization was carried out in a 96-well plate format. Approximately 10,000 HEK cells expressing the human ACE-2 receptor (HEK-ACE2) were plated in each well using L-poly-L-lysine (Millipore Sigma) to improve adherence. Equal amounts of pseudotyped lentiviruses were added to the wells (approximately 8x10<sup>4</sup> relative light units [RLU]/well) and incubated with two-fold dilutions of mouse serum starting from a 1:100 dilution. Luminescence intensity was evaluated after three days using the Pierce Firefly luciferase Glow Assay Kit (ThermoFisher), and RLUs quantified using an EnSpire Multimode Plate Reader (PerkinElmer). At 1:100 dilution, the serum of vaccinated mice showed to decrease the RLU of approximately 80-90%, compared to wells incubated with the serum of non-vaccinated mice or no serum controls (Figure S2).
Neutralization of NDV-FLS and NDV-Δ19S was done in 96 well plates, separately for mouse and chicken sera. Poly-L-lysine-coated wells were seeded with HEK-ACE-2 cells and let adhere overnight. Equal amounts of NDV-FLS or NDV-Δ19S (1,000 PFU in 50 μl) were added to each well containing 1:2 dilutions of mouse or chicken serum in 50 μl, starting from an initial 1:100 dilution. Total volume for each well was 100 μl /well, and the final solution included 5% allantoic fluid. After 3 days, the magnitude of infection was evaluated by IFA for NDV ribonucleoprotein, as described above. The amount of IFA signal in the wells tested with murine serum was quantified by image analysis (ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA), by averaging the signal intensity of the fluorescent signal using pictures from 4 different wells.

**Determination of mean death time (MDT)**

The MDT was determined for the two vaccine candidates and the control (NDV-FLS, NDV-SΔ19, and NDV-GFP). The virus stocks were equalized to a starting titer of 6.14 x 10^6 TCID₅₀/mL, and each virus stock was serially diluted from 10⁻¹ to 10⁻⁸ in PBS. Dilutions from 10⁻⁴ to 10⁻⁸ were inoculated into specific pathogen-free eggs (Canadian Food Inspection Agency) at 9 to 11 days of embryonation. For each virus, five eggs were inoculated per dilution (100 μL / egg). The experiment was run in duplicate 3 to 4 hours apart, resulting in 50 eggs used for each virus. After virus inoculation, the eggs were incubated for up to 7 days and checked twice daily for embryo mortality; after the first 24 hr after inoculation, allantoic fluid was collected from all dead embryos to check for presence of NDV by hemagglutination assay (HA), according to standards methods (McGinnes et al., 2006). The MDT was recorded as the time (in hours) taken by the minimal lethal dose (highest dilution) to kill all five eggs in the dilution series. If no minimal lethal dose was observed by the end of the experiment (seven days post-inoculation), it was concluded that the MDT was > 168 hrs, and HA was performed on the allantoic fluid collected from eggs inoculated with the lowest virus dilution (10⁻⁴) to confirm NDV infection.

**Lyophilization of NDV-FLS**

Triplicate samples of freshly harvested allantoic fluid containing NDV-FLS were aliquoted into 15mL conical tubes in 1mL volumes. Aliquots were either left untreated or adjusted to a final concentration of 5% sucrose, 5% sucrose/5% iodixanol or mixed 1:1 with a solution containing 10% lactose, 2% peptone, 10mM Tris-HCl, pH 7.6. Using an LABCONCO Freeze Dry system Freezone®4.5, samples were immediately lyophilized at 44 x 10⁻³ MBAR and -52°C for 16 hours. Lyophilized samples were stored at 4°C for 48 hours before being resuspended in 1 mL of 5% sucrose/PBS and titered. Three 1 mL aliquots of allantoic fluid containing NDV-FLS were adjusted to 5% sucrose and frozen at -70°C before titering. An additional three 1 mL aliquots were used to titer NDV-FLS in allantoic fluid immediately following harvest from eggs. All samples were titered by TCID₅₀ on DF-1 cells as described above.

To determine presence of S protein in the reconstituted preparations, lyophilized (10% lactose and 2% peptone group, only) and reconstituted NDV-FLS was compared to NDV-FLS stored at -70°C (purified preparation frozen at -70°C in sucrose). Equal amounts of virus preparations (10⁷ PFU, as determined by post-reconstitution titers) were loaded on SDS-PAGE gel, transferred to a nitrocellulose membrane and immunoblotted for the S protein using a rabbit anti-SARS-CoV-2 S2 subunit (dilution: 1:1000; NB100-56578; Novus Biologicals), as described in the previous section. To determine the ability of lyophilized and reconstituted virus to express S protein in infected cells, DF-1 cells were infected with the same amount of reconstituted or frozen virus (MOI = 0.5). Whole cell lysates were harvested 24 hrs post-infection, immunoblotting for the S protein was conducted as above.

**Immunization and infection of Syrian hamsters**

For initial immunization and booster immunization of hamsters, groups of ten Syrian Golden hamsters (five male and five female, four to six weeks of age; Charles River) were anaesthetized with inhalation isoflurane and administered 1 x 10⁷ PFU of recombinant NDV-GFP, NDV-FLS, or NDV-Δ19S via the intranasal (IN) route. For IN vaccinations, anaesthetized hamsters were scruffed and vaccines were delivered in a 100 μL volume (q.s. with PBS) through the nares (50 μL per nare). Animals had their mouths held closed to ensure inhalation through the nose. After recovery from anesthesia hamsters were monitored daily for any adverse signs following vaccine administration.

For SARS-CoV-2 infection following immunization, hamsters were moved into a CL-4 facility and then anaesthetized with inhaled isoflurane. Hamsters were then infected with 10⁵ TCID₅₀ of SARS-CoV-2 via
the same IN method described above. After recovery from anesthetic hamsters were monitored daily throughout the course of infection. Body weights and temperatures of hamsters were recorded daily.

**Microscopic pathology**

At day five post-challenge, six hamsters per group were euthanized, and the proximal and distal lobes of the lung from each hamster were sampled and fixed in 10% buffered formalin, followed by routine paraffin embedding, sectioning, and staining with hematoxylin and eosin (HE). The magnitude of microscopic lesions caused by SARS-CoV-2 in the lungs of vaccinated and control mice was evaluated histologically using two semi-quantitative scoring systems based on the presence of nominal categories (Tables S1 and S2) (Meyerholz and Beck, 2020) and extent of the pulmonary parenchyma affected (Table S3) (Imai et al., 2020). Assessment was carried out taking into consideration all the sections available for evaluation. Slides were scored by a board-certified veterinary anatomic pathologist (LS), who was blind to the treatment of the experimental groups (group de-identification).

**Detection of SARS-CoV-2 RNA in tissues and swabs of infected hamsters**

Oropharyngeal and rectal swabs were obtained and stored in MEM + 2% penicillin-streptomycin. For viral RNA detection, 140 μL of the medium containing the swab was used for viral lysis and extraction using the QIAamp Viral RNA mini kit. For viral RNA detection, tissue samples were thawed, weighed, and then homogenized in 600 μL RLT buffer (Qiagen) using a Bead Ruptor Elite Bead Mill Homogenizer (Omni International) with a stainless steel bead for at 4 m/s for 60 seconds. Viral RNA from 30 mg samples of each tissue was extracted with the RNeasy Plus Mini kit (Qiagen) according to manufacturer’s instructions, and viral RNA from swab samples was extracted with the QIAamp Viral RNA Mini kit (Qiagen) also according to manufacturer’s instructions. Detection of SARS-CoV-2 E gene was performed using TaqPath 1-Step Multiplex Master Mix kit (Applied Biosystems) and was carried out on a QuantStudio 5 real-time PCR system (Applied Biosystems), as per the manufacturer’s instructions. RNA was reverse transcribed and amplified using the primers reported by the WHO and include E_Sarbeco_F1 (5'-ACAGGTACGTTAATAGTTAATAGCGT-3') and E_Sarbeco_R2 (5'-ATATTGCAGCAGTCAGCACACA-3') and probe E_Sarbeco_P1 (5'-FAM-ACACTGCCATCCTTACTGCGCTTCG-BQQ-3'). A standard curve produced with synthesized target DNA was run with every plate and used for the interpolation of viral genome copy numbers.

**Detection of infectious SARS-CoV-2 in tissues and swabs of infected hamsters**

For infectious virus assays, thawed tissue samples were weighed and placed in 1 mL of minimum essential medium supplemented with 1% heat-inactivated fetal bovine serum (FBS) and 1x L-glutamine, then homogenized in a Bead Ruptor Elite Bead Mill Homogenizer (Omni International) at 4 m/s for 30 seconds then clarified by centrifugation at 1,500 xg for 10 minutes. Prior to titration procedures, oropharyngeal and rectal swabs stored in MEM + 2% penicillin-streptomycin were vortexed and centrifuged briefly. Samples were serially diluted 10-fold in media and dilutions were then added to 96-well plates of 95% confluent Vero cells containing 50 μL of the same medium in replicates of three and incubated for five days at 37°C with 5% CO₂. Plates were scored for the presence of cytopathic effect on day five after infection. Titers were calculated using the Reed-Muench method, and reported as TCID₅₀ units.

**Determination of antibody responses by ELISA and PRNT assay**

For detection of anti-SARS-CoV-2-specific antibody responses, all hamsters were bled via jugular vein bleeds for serum on days 21, 29, 49, and 56 post-first vaccination. For ELISAs for detection of total IgG detection, SARS-CoV-2 spike- and nucleoprotein-specific responses were assessed using an in-house assay. A 1:400 dilution of serum was carried out in duplicate and added to plates pre-coated with both spike and nucleoprotein in the same assay wells. IgG was detected with a peroxidase-labeled polyclonal goat anti-hamster IgG (H+L) (KPL). For virus PRNT (plaque reduction neutralization assays), serum samples were heat-inactivated at 56°C for 30 minutes and diluted two-fold from 1:40 to 1:1280 in DMEM supplemented with 2% FBS. Diluted sera were incubated with 50 PFU of SARS-CoV-2 at 37°C and 5% CO₂ for 1 hour. The sera-virus mixture were added to 24-well plates containing Vero E6 cells at 100% confluence, followed by incubation at 37°C and 5% CO₂ for 1 hour. After adsorption, 1.5% carboxymethylcellulose diluted in MEM supplemented with 4% FBS, L-glutamine, non-essential amino acids, and sodium bicarbonate was added to each well and plates were incubated at 37°C and 5% CO₂ for 72 hours. The liquid overlay was removed and cells were
fixed with 10% neutral-buffered formalin for 1 hour at room temperature. The monolayers were stained with 0.5% crystal violet for 10 minutes and washed with 20% ethanol. Plaques were enumerated and compared to a 90% neutralization control. The PRNT-90 endpoint titer was defined as the highest serum dilution resulting in a 90% reduction in the number of plaques. PRNT-90 titers ≥ 1:40 were considered positive for neutralizing antibodies.

**Hematological and biochemical analysis of blood and serum**

Complete blood counts were carried out using a VetScan HM5 hematology system (Abaxis Veterinary Diagnostics), as per the manufacturer’s instructions. Analysis of serum biochemistry was performed with a VetScan VS2 analyzer (Abaxis Veterinary Diagnostics), as per the manufacturer’s instructions.

**Cytokine mRNA analysis**

RNA was extracted from proximal lung samples as described above using a RNeasy Plus Mini Kit (Qiagen), which includes a genomic DNA elimination step, as per the manufacturer’s instructions. Expression of IFNγ, IL-2, IL-4, IL-10, IL-1b, FoxP3, TGF-β, VEGF, IL-6, and TNFα mRNA was analyzed using the one-step TaqPath Master Mix kit using the primer/probe sets described previously (Warner et al., 2017). Ribosomal protein L18 (RPL18) was used as an internal control. All RT-qPCR assays were performed on a QuantStudio 5 instrument (Applied Biosystems). Expression is reported as Log2 of the fold-change for each gene as calculated using the ΔΔCt method compared with expression of the same genes in sex-matched control tissues that were unvaccinated and uninfected.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Mean scores between experimental groups were compared using analysis of variance (ANOVA) with Tukey’s post-hoc (lyophilization experiment) or Holm Sidak (neutralization) tests for multiple comparisons, two-way ANOVA (serology), non-parametric Mann-Whitney or Kruskal-Wallis test followed by the Dunn’s method for multiple comparisons (all other tests and pathology data), with significance set at p < 0.05 as implemented in GraphPad software version 8.0.0 (San Diego, California, USA, www.graphpad.com). Data are represented as scatterplots with median, median with range, or average with standard deviation (see figure legends).